Abbott Laboratories (ABT) vs Regeneron Pharmaceuticals (REGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Regeneron Pharmaceuticals (REGN) has outperformed Abbott Laboratories (ABT) over the past year, gaining 27.2% versus a loss of 25.8%. Over five years, REGN leads with a +34.1% price change compared with -16.0% for ABT. Abbott Laboratories is the larger company by market cap ($168.44 billion vs $74.74 billion), about 2.3 times the size.
On valuation, Regeneron Pharmaceuticals trades at a lower forward P/E (11.8x vs 16.0x for Abbott Laboratories). Abbott Laboratories offers the higher dividend yield (2.55% vs 0.50%). Regeneron Pharmaceuticals converts more of its revenue into profit, with a net margin of 31.4% versus 14.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABT | REGN |
|---|---|---|
| Share price | $97.34 | $725.98 |
| Market cap | $168.44B | $74.74B |
| 1-day change | -1.41% | -2.17% |
| YTD return | -21.20% | -3.85% |
| 1-year return | -25.78% | +27.24% |
| 5-year return | -15.97% | +34.14% |
| P/E ratio (TTM) | 31.40 | 17.95 |
| Forward P/E | 16.05 | 11.81 |
| EPS (TTM) | $3.10 | $40.44 |
| Dividend yield | 2.55% | 0.50% |
| Annual dividend | $2.48 | $3.64 |
| Revenue (latest FY) | $44.33B | $14.34B |
| Revenue growth (YoY) | +5.67% | +0.99% |
| Net income (latest FY) | $6.52B | $4.50B |
| Gross margin | 56.42% | — |
| Operating margin | 18.17% | 24.95% |
| Net margin | 14.72% | 31.41% |
| 52-week high | $135.13 | $859.34 |
| 52-week low | $81.97 | $541.00 |
| Distance from 52-week high | -27.97% | -15.52% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +24.02% | +17.94% |
| Average volume | 9.56M | 739.67K |
| Shares outstanding | 1.73B | 101.14M |
| Employees | 122,000 | 15,410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Abbott Laboratories is about 2.3 times larger than Regeneron Pharmaceuticals by market value ($168.44B vs $74.74B).
- REGN has outperformed ABT by 53.0 percentage points over the past year.
- Abbott Laboratories trades at a higher earnings multiple (31.4x vs 18.0x trailing P/E).
- Abbott Laboratories offers a meaningfully higher dividend yield (2.55% vs 0.50%).
- Regeneron Pharmaceuticals is more profitable, keeping 31.4 cents of every revenue dollar as net income versus 14.7 cents for Abbott Laboratories.
About Abbott Laboratories
ABT stock →Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Health Care · Biotechnology: Pharmaceutical Preparations · 122,000 employees
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
ABT vs REGN FAQ
Which is bigger, Abbott Laboratories or Regeneron Pharmaceuticals?
Abbott Laboratories (ABT) is larger, with a market capitalization of $168.44B compared with $74.74B for Regeneron Pharmaceuticals (REGN).
Which stock has performed better over the past year, ABT or REGN?
REGN returned +27.24% over the past 12 months, compared with -25.78% for ABT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABT or REGN?
REGN has the lower trailing P/E at 18.0, versus 31.4 for ABT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Abbott Laboratories or Regeneron Pharmaceuticals?
Abbott Laboratories has the higher yield at 2.55%, compared with 0.50% for Regeneron Pharmaceuticals.
Are Abbott Laboratories and Regeneron Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.